Light Sciences Oncology, the Bellevue, WA-based developer of a technology that combines a drug with a light-emitting diode to kill tumors, said today it has completed enrollment in a pivotal clinical trial of patients with colorectal cancer that has spread to the liver. The trial enrolled 450 patients who were randomly assigned to get talaporfin sodium (Aptocine) plus chemotherapy, or the chemotherapy alone. The study is examining whether the new drug can keep the cancer from spreading further, and help people live longer. Results are expected later this year, the company said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
